Meeting
2011 Breast Cancer Symposium
Role of HER2 status in the treatment of brain metastases arising from breast cancer by stereotactic radiosurgery.
Authors
Y. Novik
New York University Langone Medical Center, New York University Cancer Institute, New York, NY
Y. Novik , S. Kunnakkat , B. Donahue , S. Rush , J. Golfinos , E. Parker , A. Narayana
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Reception and General Poster Session B
Track
Local/Regional Therapy
Sub Track
Radiation and Radiobiology
Citation
J Clin Oncol 29, 2011 (suppl 27; abstr 117)
Abstract #
117
Poster Bd #
B18
Abstract Disclosures
Similar Posters
Poster
2014 Breast Cancer Symposium
Effect of tumor subtype on overall survival in brain metastatic breast cancer patients treated with cranial irradiation.
First Author: Vipin Das Villgran
Poster
2023 ASCO Annual Meeting
Preclinical and early clinical data of ZN-1041, a best-in-class BBB penetrable HER2 inhibitor to treat breast cancer with CNS metastases.
First Author: Fei Ma
Poster
2023 ASCO Annual Meeting
Phase I/II study of stereotactic radiosurgery with concurrent olaparib followed by adjuvant durvalumab and physician’s choice systemic therapy in patients with breast cancer brain metastases.
First Author: Colette Shen
Poster
2021 ASCO Annual Meeting
Heterogeneity of HER2 expression in circulating tumor cells of patients with breast cancer brain metastases and impact on brain disease control.
First Author: Douglas Guedes Castro